Satellos Bioscience (TSE:MSCL) has released an update.
Satellos Bioscience Inc. has reached a critical milestone by submitting a proposal to conduct a Phase 1 clinical trial for its new drug SAT-3247, aimed at treating muscle diseases. The trial is set to begin in the third quarter of 2024, signaling the company’s transition to a clinical-stage entity. SAT-3247, an oral small molecule drug, shows promise in regenerating skeletal muscle affected by conditions like Duchenne muscular dystrophy.
For further insights into TSE:MSCL stock, check out TipRanks’ Stock Analysis page.
